Monoclonal antibody · Antagonist of pathological tau (MAPT) · developed by Voyager Therapeutics
VY7523 is a humanized IgG4 monoclonal antibody that binds pathological tau protein. It is being studied in Alzheimer's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06874621 | Phase 1/2 | Alzheimer's Disease (AD) | Active not recruiting | VYGR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer's Disease (AD)
Updated Nov 1, 2026. Something wrong or missing? Report it on the VYGR page.
See VYGR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VYGR catalysts and pipeline →